Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Arrowhead Pharmaceuticals is a clinical-stage biotechnology company developing RNA interference (RNAi) therapeutics using its proprietary TRiM platform technology. The company focuses on intractable diseases in cardio-metabolic, pulmonary, and rare disease areas, with lead programs targeting NASH, cardiovascular disease, and alpha-1 antitrypsin deficiency. The dramatic revenue growth reflects transition from pure R&D to commercialization partnerships and milestone payments.
Arrowhead monetizes its TRiM (Targeted RNAi Molecule) platform through strategic partnerships with large pharmaceutical companies, receiving upfront payments, research funding, clinical milestone payments, and future royalty streams. The 97.1% gross margin reflects the high-margin nature of IP licensing and milestone revenue with minimal direct costs. The company retains rights to certain wholly-owned programs while out-licensing others to de-risk development costs. Pricing power derives from the proprietary nature of its delivery technology and the lack of effective treatments for target indications. The platform's ability to silence virtually any gene creates optionality across multiple therapeutic areas.
Clinical trial data readouts for lead programs (plozasiran for cardiovascular disease, zodasiran for NASH, fazirsiran for alpha-1 antitrypsin deficiency)
New partnership announcements and upfront/milestone payment disclosures with specific dollar amounts
FDA regulatory decisions including IND clearances, Fast Track designations, and breakthrough therapy designations
Competitive clinical data from rival RNAi platforms (Alnylam, Dicerna/Novo Nordisk, Silence Therapeutics)
Broader biotech sector sentiment and risk appetite for clinical-stage assets
Clinical trial failure risk across multiple programs, particularly for lead assets in Phase 2/3 trials where efficacy and safety must meet regulatory thresholds
Competitive pressure from established RNAi players (Alnylam with 4 approved products) and emerging modalities (base editing, CRISPR) that could offer superior efficacy or safety profiles
Regulatory pathway uncertainty for novel RNA therapeutics, including potential FDA requirements for long-term safety data given limited class history
Reimbursement challenges for high-cost genetic medicines in cost-constrained healthcare systems, potentially limiting commercial opportunity even with approval
Alnylam's first-mover advantage in RNAi with established manufacturing, regulatory expertise, and four marketed products creating high barriers to entry
Large pharmaceutical companies developing internal RNAi capabilities, reducing dependence on platform partnerships
Competition in specific indications (NASH, cardiovascular) from well-funded programs using alternative mechanisms (GLP-1 agonists, PCSK9 inhibitors, FXR agonists)
Cash burn risk if clinical programs require larger-than-expected trials or encounter delays, though current 3.38x current ratio suggests 2-3 year runway at current burn
Dilution risk from future equity financings to fund wholly-owned programs through commercialization if partnership revenue proves insufficient
Debt/equity ratio of 0.55 is manageable but represents obligations that must be serviced regardless of clinical outcomes
low - As a pre-commercial biotech, revenue is driven by clinical milestones and partnership agreements rather than economic cycles. However, severe recessions can impact: (1) pharmaceutical partners' willingness to commit capital to new collaborations, (2) ability to raise capital at attractive valuations, and (3) M&A activity as potential exit opportunities. The company's 3.38x current ratio provides substantial liquidity buffer against cyclical funding disruptions.
Rising interest rates create multiple headwinds: (1) higher discount rates compress NPV of distant cash flows from late-stage programs, disproportionately impacting clinical-stage biotechs, (2) increased competition from risk-free yields reduces investor appetite for speculative biotech exposure, (3) higher cost of capital for future financings. The 8.2x price/sales multiple reflects growth expectations highly sensitive to discount rate assumptions. Conversely, falling rates typically drive biotech multiple expansion.
Minimal direct credit exposure. The company is not dependent on credit markets for operations given strong current ratio and positive operating cash flow. However, credit conditions indirectly affect: (1) pharmaceutical partners' balance sheets and deal-making capacity, (2) biotech sector financing environment for future capital raises, (3) M&A valuations if acquisition becomes strategic option.
growth - The 212.6% one-year return and 8.2x price/sales multiple reflect speculative growth investor positioning. Investors are betting on clinical trial success converting to either: (1) substantial milestone/royalty revenue streams from partnerships, or (2) acquisition premium from large pharma seeking RNAi capabilities. The negative net margin and minimal current revenue make this unsuitable for value or income investors. The 215.9% six-month return indicates strong momentum investor participation. Typical holders include biotech-focused hedge funds, venture capital crossover funds, and growth-oriented institutional investors with high risk tolerance and 3-5 year time horizons aligned with clinical development timelines.
high - Clinical-stage biotechs exhibit extreme volatility around binary events (trial data, FDA decisions, partnership announcements). The 50.5% three-month return demonstrates the magnitude of price swings. Stock typically trades on low volume with wide bid-ask spreads, amplifying volatility. Beta likely exceeds 1.5x relative to biotech indices. Options implied volatility typically elevated (60-100%+) ahead of data catalysts. Not suitable for risk-averse investors or those requiring portfolio stability.
